Center for Oncoendocrinology Provides Care for Cancer Patients with Endocrine Conditions

The Center for Oncoendocrinology at Brigham and Women’s Hospital was established to provide expert endocrine care for cancer patients during and after treatment. Endocrinologists at the Center, a program of Dana-Farber/Brigham and Women’s Cancer Center, can provide specialized knowledge of endocrine issues that may affect your cancer patient.

Read More

Intensive Diabetes Management Program Lowers A1C Levels in Complex Patients

The Setting Targets Achieving Results Diabetes Mellitus (STAR-DM) Program at Brigham and Women’s Hospital (BWH) offers your high-risk diabetes patients an intensive management program to meet their clinical targets, such as achieving their A1C target or avoiding too-low blood glucose.

Read More

New Class of Type 2 Diabetes Drug Associated with Rare, Life-threatening Outcome

A new class of drugs, known as SGLT2 inhibitors, is increasingly being prescribed for the treatment of Type 2 diabetes, but may increase the risk of a rare but serious complication known as diabetic ketoacidosis.   

Read More

New Blood Test May Better Predict Gestational Diabetes 

A new study led by researchers at Brigham and Women’s Hospital (BWH) has found that a single measurement of plasma glycated CD59 (GCD59), a novel biomarker for diabetes, at weeks 24-28 of gestation identified, with high sensitivity and specificity, women who failed the glucose challenge test as well as women with gestational diabetes. Plasma levels of GCD59 were also associated with the probability of delivering a large-for-gestational-age newborn. These findings were published in Diabetes Care. Read More

Insulin Therapy Initially Declined and Delayed by an Average of Two Years 

Alexander Turchin

Although delaying insulin therapy leads to worsening of diabetes, new research by Brigham and Women’s Hospital (BWH) has found that 30 percent of patients with type 2 diabetes don’t begin insulin, a medication used to lower the body’s blood sugar levels, when it’s initially recommended, with the average start time being two years later. These findings were published today in the journal, Diabetic Medicine. Read More